New hope for asian brain tumor patients: targeted pill slows cancer growth
NCT ID NCT06780930
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental pill, vorasidenib, in Asian patients with a slow-growing but serious brain tumor (grade 2 glioma) that has a specific genetic mutation (IDH1 or IDH2). About 57 participants will receive either the drug or a placebo to see if it delays tumor progression. The goal is to offer a less toxic alternative to chemotherapy or radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESIDUAL OR RECURRENT GRADE 2 IDH MUTANT GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chang Gung Memorial Hospital,
Taoyuan, Taiwan
-
Huashan Hospital Fudan University
Shanghai, 200040, China
-
Sanbo Brain Hospital, Capital Medical University
Beijing, China
-
Taipei Veterans General Hospital
Taipei, Taiwan
-
The Second Affiliated Hospital of Air Force Military Medical University
Xi'an, China
-
The Second People's Hospital of Shenzhen
Shenzhen, Guangdong, China
-
Tiantan Hospital
Beijing, 100070, China
-
West China Hospital Sichuan University
Chengdu, Sichuan, China